Global Parkinson’s disease Therapeutics Market: Industry Analysis and forecast (2019 to 2026): By Drug Class, Route of Administration Analysis, Route of Administration Analysis and Region


Global Parkinson’s disease Therapeutics Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 11 % during forecast period of 2019 to 2026.

Global Parkinson’s disease Therapeutics MarketTo know about the Research Methodology :- Request Free Sample Report

Parkinson's disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. It is largely prevalent among the geriatric population.
Global Parkinson’s disease Therapeutics Market by key segmentation
The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
Oral route of administration, followed by intestinal infusion segment, dominates the global market. More than 80% of the drugs available for treatment of Parkinson's disease are in the form of tablet and capsule. Some of the drugs are orally disintegrated. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson's disease are estimated to limit the growth of the oral route of administration segment by the end of 2026.

Retail pharmacy followed by hospital pharmacy segment, dominates the market. Among distribution channels, the retail pharmacy segment is projected to hold largest share of global market hold the dominant share of the global Parkinson's disease therapeutics market during the forecast period and is likely to expand the global market. Easy availability of Parkinson's therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The online pharmacy segment is poised to grow at as significant CAGR during the forecast period.

Global Parkinson’s disease Therapeutics Market by drivers and restraints

Recent advances in Parkinson’s disease therapeutics such as combination therapies to prolong the action of continuous dopaminergic stimulation drugs, approval for neurostimulation devices and neuroprotective therapies to slow down prognosis of a disease, gene therapy, neural transplantation etc., are expected to bring rapid growth in global Parkinson’s disease therapeutics market over the forecast period.

Aging population and prevalence of Parkinsonism across the world are the factors fueling demand for Parkinson’s disease therapeutics. However, expiry of patents for several drugs such as Rytary, Stalevo (2012), Azilect (2017), Comtan (exclusivity expired in 2013) would hinder the global Parkinson’s disease therapeutics Market in forecast period.

Global Parkinson’s disease Therapeutics Market by regional analysis

North America Held largest share in global Parkinson’s disease Therapeutics Market. According to Parkinson’s disease Foundation (PDF) approximately XX thousand Americans are diagnosed with Parkinson’s disease annually. Europe is expected to hold second highest share in the global market. Large number of key players focusing on research and developments activities to introduce technologically-advanced Parkinson’s disease Therapeutics with better designs drive the market in the region.

The objective of the report is to present comprehensive analysis of Global Parkinson’s Disease Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Parkinson’s Disease Therapeutics Market dynamics, structure by analyzing the market segments, and project the Global Parkinson’s Disease Therapeutics Market size. Clear representation of competitive analysis of key players by Parkinson’s Disease Therapeutics Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Parkinson’s Disease Therapeutics Market make the report investor’s guide.

Scope of the Global Parkinson’s disease Therapeutics Market: Inquire before buying


Global Parkinson’s disease Therapeutics Market by Drug Class

• Levodopa Combination
• Dopamine Agonists
• Monoamine Oxidase B (Mao-B) Inhibitors
• Anticholinergic Drugs
• Catechol-O-Methyltransferase (COMT) Inhibitors

Global Parkinson’s disease Therapeutics Market by Route of Administration Analysis

• Oral
• Transdermal
• Subcutaneous
• Intestinal Infusion

Global Parkinson’s disease Therapeutics Market by Distribution Channel Analysis

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales

Global Parkinson’s disease Therapeutics Market by region

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Key players operating on Global Parkinson’s disease Therapeutics Market

• GlaxoSmithKline Plc.,
• Salix Pharmaceuticals,
• map Laboratories, Inc.,
• Teva Pharmaceutical Industries Ltd.,
• Novartis AG, Orion Corporation,
• Mylan N.V.
• Abbvie, Inc.
• Biogen, Inc.
• Boehringer Ingelheim GmbH
• F. Hoffman-La Roche
• GlaxoSmithKline Plc.
• H. Lundbeck A/S
• Impax Labs, Inc.
• Newron Pharmaceuticals SpA
• Novartis AG
• Orion Corporation
• UCB S.A.
• Supernus Pharmaceuticals
• Desitin Arzneimittel GmbH
• Adamas Pharmaceutical Inc.
• Amneal Pharmaceuticals
• Sumitoma Dainippon pharma co ltd
• Acorda Therapeutics Inc
• Acadia Pharmaceuticals
• Kyowa Kirin Inc

  




Global Parkinson’s disease Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Parkinson’s disease Therapeutics Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Parkinson’s disease Therapeutics Market Analysis and Forecast
6.1. Global Parkinson’s disease Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Drug class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
7.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Drug class
7.5. Global Parkinson’s disease Therapeutics Market Analysis, by Drug class
7.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Drug class

8. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Administration route
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
8.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Administration route
8.5. Global Parkinson’s disease Therapeutics Market Analysis, by Administration route
8.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Administration route

9. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Distribution channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
9.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Distribution channel
9.5. Global Parkinson’s disease Therapeutics Market Analysis, by Distribution channel
9.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Distribution channel

10. Global Parkinson’s disease Therapeutics Market Analysis, by Region
10.1. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Region
10.2. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Region
10.3. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Region

11. North America Parkinson’s disease Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Parkinson’s disease Therapeutics Market Overview
11.3. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
11.4. North America Parkinson’s disease Therapeutics Market Forecast, by Drug class
11.4.1. Levodopa Combination
11.4.2. Dopamine Agonists
11.4.3. Monoamine Oxidase B (Mao-B) Inhibitors
11.4.4. Anticholinergic Drugs
11.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors
11.5. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
11.6. North America Parkinson’s disease Therapeutics Market Forecast, by Administration route
11.6.1. Oral
11.6.2. Transdermal
11.6.3. Subcutaneous
11.6.4. Intestinal Infusion
11.7. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
11.8. North America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
11.8.1. Hospital Pharmacy
11.8.2. Retail Pharmacy
11.8.3. Online Sales
11.9. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Country
11.10. North America Parkinson’s disease Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Parkinson’s disease Therapeutics Market Analysis, by Country
11.12. U.S. Parkinson’s disease Therapeutics Market Forecast, by Drug class
11.12.1. Levodopa Combination
11.12.2. Dopamine Agonists
11.12.3. Monoamine Oxidase B (Mao-B) Inhibitors
11.12.4. Anticholinergic Drugs
11.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors
11.13. U.S. Parkinson’s disease Therapeutics Market Forecast, by Administration route
11.13.1. Oral
11.13.2. Transdermal
11.13.3. Subcutaneous
11.13.4. Intestinal Infusion
11.14. U.S. Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
11.14.1. Hospital Pharmacy
11.14.2. Retail Pharmacy
11.14.3. Online Sales
11.15. Canada Parkinson’s disease Therapeutics Market Forecast, by Drug class
11.15.1. Levodopa Combination
11.15.2. Dopamine Agonists
11.15.3. Monoamine Oxidase B (Mao-B) Inhibitors
11.15.4. Anticholinergic Drugs
11.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors
11.16. Steel Canada Parkinson’s disease Therapeutics Market Forecast, by Administration route
11.16.1. Oral
11.16.2. Transdermal
11.16.3. Subcutaneous
11.16.4. Intestinal Infusion
11.17. Canada Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
11.17.1. Hospital Pharmacy
11.17.2. Retail Pharmacy
11.17.3. Online Sales
11.18. North America Parkinson’s disease Therapeutics Market Attractiveness Analysis
11.18.1. By Drug class
11.18.2. By Administration route
11.18.3. By Distribution channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Parkinson’s disease Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Parkinson’s disease Therapeutics Market Overview
12.3. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
12.4. Europe Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.4.1. Levodopa Combination
12.4.2. Dopamine Agonists
12.4.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.4.4. Anticholinergic Drugs
12.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.5. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
12.6. Europe Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.6.1. Oral
12.6.2. Transdermal
12.6.3. Subcutaneous
12.6.4. Intestinal Infusion
12.7. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
12.8. Europe Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.8.1. Hospital Pharmacy
12.8.2. Retail Pharmacy
12.8.3. Online Sales
12.9. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Country
12.10. Europe Parkinson’s disease Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Parkinson’s disease Therapeutics Market Analysis, by Country
12.12. Germany Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.12.1. Levodopa Combination
12.12.2. Dopamine Agonists
12.12.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.12.4. Anticholinergic Drugs
12.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.13. Germany Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.13.1. Oral
12.13.2. Transdermal
12.13.3. Subcutaneous
12.13.4. Intestinal Infusion
12.14. Germany Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.14.1. Hospital Pharmacy
12.14.2. Retail Pharmacy
12.14.3. Online Sales
12.15. U.K. Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.15.1. Levodopa Combination
12.15.2. Dopamine Agonists
12.15.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.15.4. Anticholinergic Drugs
12.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.16. U.K. Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.16.1. Oral
12.16.2. Transdermal
12.16.3. Subcutaneous
12.16.4. Intestinal Infusion
12.17. U.K. Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.17.1. Hospital Pharmacy
12.17.2. Retail Pharmacy
12.17.3. Online Sales
12.18. France Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.18.1. Levodopa Combination
12.18.2. Dopamine Agonists
12.18.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.18.4. Anticholinergic Drugs
12.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.19. France Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.19.1. Oral
12.19.2. Transdermal
12.19.3. Subcutaneous
12.19.4. Intestinal Infusion
12.20. France Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.20.1. Hospital Pharmacy
12.20.2. Retail Pharmacy
12.20.3. Online Sales
12.21. Italy Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.21.1. Levodopa Combination
12.21.2. Dopamine Agonists
12.21.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.21.4. Anticholinergic Drugs
12.21.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.22. Italy Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.22.1. Oral
12.22.2. Transdermal
12.22.3. Subcutaneous
12.22.4. Intestinal Infusion
12.23. Italy Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.23.1. Hospital Pharmacy
12.23.2. Retail Pharmacy
12.23.3. Online Sales
12.24. Spain Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.24.1. Levodopa Combination
12.24.2. Dopamine Agonists
12.24.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.24.4. Anticholinergic Drugs
12.24.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.25. Spain Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.25.1. Oral
12.25.2. Transdermal
12.25.3. Subcutaneous
12.25.4. Intestinal Infusion
12.26. Spain Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.26.1. Hospital Pharmacy
12.26.2. Retail Pharmacy
12.26.3. Online Sales
12.27. Rest of Europe Parkinson’s disease Therapeutics Market Forecast, by Drug class
12.27.1. Levodopa Combination
12.27.2. Dopamine Agonists
12.27.3. Monoamine Oxidase B (Mao-B) Inhibitors
12.27.4. Anticholinergic Drugs
12.27.5. Catechol-O-Methyltransferase (COMT) Inhibitors
12.28. Rest of Europe Parkinson’s disease Therapeutics Market Forecast, by Administration route
12.28.1. Oral
12.28.2. Transdermal
12.28.3. Subcutaneous
12.28.4. Intestinal Infusion
12.29. Rest Of Europe Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
12.29.1. Hospital Pharmacy
12.29.2. Retail Pharmacy
12.29.3. Online Sales
12.30. Europe Parkinson’s disease Therapeutics Market Attractiveness Analysis
12.30.1. By Drug class
12.30.2. By Administration route
12.30.3. By Distribution channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Parkinson’s disease Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Parkinson’s disease Therapeutics Market Overview
13.3. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
13.4. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.4.1. Levodopa Combination
13.4.2. Dopamine Agonists
13.4.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.4.4. Anticholinergic Drugs
13.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.5. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
13.6. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.6.1. Oral
13.6.2. Transdermal
13.6.3. Subcutaneous
13.6.4. Intestinal Infusion
13.7. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
13.8. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.8.1. Hospital Pharmacy
13.8.2. Retail Pharmacy
13.8.3. Online Sales
13.9. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Parkinson’s disease Therapeutics Market Analysis, by Country
13.12. China Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.12.1. Levodopa Combination
13.12.2. Dopamine Agonists
13.12.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.12.4. Anticholinergic Drugs
13.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.13. China Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.13.1. Oral
13.13.2. Transdermal
13.13.3. Subcutaneous
13.13.4. Intestinal Infusion
13.14. China Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.14.1. Hospital Pharmacy
13.14.2. Retail Pharmacy
13.14.3. Online Sales
13.15. India Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.15.1. Levodopa Combination
13.15.2. Dopamine Agonists
13.15.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.15.4. Anticholinergic Drugs
13.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.16. India Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.16.1. Oral
13.16.2. Transdermal
13.16.3. Subcutaneous
13.16.4. Intestinal Infusion
13.17. India Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.17.1. Hospital Pharmacy
13.17.2. Retail Pharmacy
13.17.3. Online Sales
13.18. Japan Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.18.1. Levodopa Combination
13.18.2. Dopamine Agonists
13.18.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.18.4. Anticholinergic Drugs
13.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.19. Japan Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.19.1. Oral
13.19.2. Transdermal
13.19.3. Subcutaneous
13.19.4. Intestinal Infusion
13.20. Japan Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.20.1. Hospital Pharmacy
13.20.2. Retail Pharmacy
13.20.3. Online Sales
13.21. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.21.1. Levodopa Combination
13.21.2. Dopamine Agonists
13.21.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.21.4. Anticholinergic Drugs
13.21.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.22. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.22.1. Oral
13.22.2. Transdermal
13.22.3. Subcutaneous
13.22.4. Intestinal Infusion
13.23. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.23.1. Hospital Pharmacy
13.23.2. Retail Pharmacy
13.23.3. Online Sales
13.24. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Drug class
13.24.1. Levodopa Combination
13.24.2. Dopamine Agonists
13.24.3. Monoamine Oxidase B (Mao-B) Inhibitors
13.24.4. Anticholinergic Drugs
13.24.5. Catechol-O-Methyltransferase (COMT) Inhibitors
13.25. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Administration route
13.25.1. Oral
13.25.2. Transdermal
13.25.3. Subcutaneous
13.25.4. Intestinal Infusion
13.26. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
13.26.1. Hospital Pharmacy
13.26.2. Retail Pharmacy
13.26.3. Online Sales
13.27. Asia Pacific Parkinson’s disease Therapeutics Market Attractiveness Analysis
13.27.1. By Drug class
13.27.2. By Administration route
13.27.3. By Distribution channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Parkinson’s disease Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Parkinson’s disease Therapeutics Market Overview
14.3. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
14.4. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class
14.4.1. Levodopa Combination
14.4.2. Dopamine Agonists
14.4.3. Monoamine Oxidase B (Mao-B) Inhibitors
14.4.4. Anticholinergic Drugs
14.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors
14.5. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
14.6. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route
14.6.1. Oral
14.6.2. Transdermal
14.6.3. Subcutaneous
14.6.4. Intestinal Infusion
14.7. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
14.8. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
14.8.1. Hospital Pharmacy
14.8.2. Retail Pharmacy
14.8.3. Online Sales
14.9. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Parkinson’s disease Therapeutics Market Analysis, by Country
14.12. GCC Parkinson’s disease Therapeutics Market Forecast, by Drug class
14.12.1. Levodopa Combination
14.12.2. Dopamine Agonists
14.12.3. Monoamine Oxidase B (Mao-B) Inhibitors
14.12.4. Anticholinergic Drugs
14.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors
14.13. GCC Parkinson’s disease Therapeutics Market Forecast, by Administration route
14.13.1. Oral
14.13.2. Transdermal
14.13.3. Subcutaneous
14.13.4. Intestinal Infusion
14.14. GCC Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
14.14.1. Hospital Pharmacy
14.14.2. Retail Pharmacy
14.14.3. Online Sales
14.15. South Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class
14.15.1. Levodopa Combination
14.15.2. Dopamine Agonists
14.15.3. Monoamine Oxidase B (Mao-B) Inhibitors
14.15.4. Anticholinergic Drugs
14.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors
14.16. South Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route
14.16.1. Oral
14.16.2. Transdermal
14.16.3. Subcutaneous
14.16.4. Intestinal Infusion
14.17. South Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
14.17.1. Hospital Pharmacy
14.17.2. Retail Pharmacy
14.17.3. Online Sales
14.18. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class
14.18.1. Levodopa Combination
14.18.2. Dopamine Agonists
14.18.3. Monoamine Oxidase B (Mao-B) Inhibitors
14.18.4. Anticholinergic Drugs
14.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors
14.19. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route
14.19.1. Oral
14.19.2. Transdermal
14.19.3. Subcutaneous
14.19.4. Intestinal Infusion
14.20. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
14.20.1. Hospital Pharmacy
14.20.2. Retail Pharmacy
14.20.3. Online Sales
14.21. Middle East & Africa Parkinson’s disease Therapeutics Market Attractiveness Analysis
14.21.1. By Drug class
14.21.2. By Administration route
14.21.3. By Distribution channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Parkinson’s disease Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Parkinson’s disease Therapeutics Market Overview
15.3. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class
15.4. South America Parkinson’s disease Therapeutics Market Forecast, by Drug class
15.4.1. Levodopa Combination
15.4.2. Dopamine Agonists
15.4.3. Monoamine Oxidase B (Mao-B) Inhibitors
15.4.4. Anticholinergic Drugs
15.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors
15.5. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route
15.6. South America Parkinson’s disease Therapeutics Market Forecast, by Administration route
15.6.1. On-Premises
15.6.2. Cloud
15.7. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel
15.8. South America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
15.8.1. Hospital Pharmacy
15.8.2. Retail Pharmacy
15.8.3. Online Sales

15.9. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Country
15.10. South America Parkinson’s disease Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Parkinson’s disease Therapeutics Market Analysis, by Country
15.12. Brazil Parkinson’s disease Therapeutics Market Forecast, by Drug class
15.12.1. Levodopa Combination
15.12.2. Dopamine Agonists
15.12.3. Monoamine Oxidase B (Mao-B) Inhibitors
15.12.4. Anticholinergic Drugs
15.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors
15.13. Brazil Parkinson’s disease Therapeutics Market Forecast, by Administration route
15.13.1. Oral
15.13.2. Transdermal
15.13.3. Subcutaneous
15.13.4. Intestinal Infusion
15.14. Brazil Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
15.14.1. Hospital Pharmacy
15.14.2. Retail Pharmacy
15.14.3. Online Sales
15.15. Mexico Parkinson’s disease Therapeutics Market Forecast, by Drug class
15.15.1. Levodopa Combination
15.15.2. Dopamine Agonists
15.15.3. Monoamine Oxidase B (Mao-B) Inhibitors
15.15.4. Anticholinergic Drugs
15.15.5. Catechol-O-Methyl transferase (COMT) Inhibitors
15.16. Mexico Parkinson’s disease Therapeutics Market Forecast, by Administration route
15.16.1. Oral
15.16.2. Transdermal
15.16.3. Subcutaneous
15.16.4. Intestinal Infusion
15.17. Mexico Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
15.17.1. Hospital Pharmacy
15.17.2. Retail Pharmacy
15.17.3. Online Sales
15.18. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Drug class
15.18.1. Levodopa Combination
15.18.2. Dopamine Agonists
15.18.3. Monoamine Oxidase B (Mao-B) Inhibitors
15.18.4. Anticholinergic Drugs
15.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors
15.19. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Administration route
15.19.1. Oral
15.19.2. Transdermal
15.19.3. Subcutaneous
15.19.4. Intestinal Infusion
15.20. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel
15.20.1. Hospital Pharmacy
15.20.2. Retail Pharmacy
15.20.3. Online Sales
15.21. South America Parkinson’s disease Therapeutics Market Attractiveness Analysis
15.21.1. By Drug class
15.21.2. By Administration route
15.21.3. By Distribution channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. GlaxoSmithKline Plc.,
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint

16.3.2. Salix Pharmaceuticals,
16.3.3. mpax Laboratories, Inc.,
16.3.4. Teva Pharmaceutical Industries Ltd.,
16.3.5. Novartis AG, Orion Corporation,
16.3.6. Mylan N.V.
16.3.7. Abbvie, Inc.
16.3.8. Biogen, Inc.
16.3.9. Boehringer Ingelheim GmbH
16.3.10. F. Hoffman-La Roche
16.3.11. GlaxoSmithKline Plc.
16.3.12. H. Lundbeck A/S
16.3.13. Impax Labs, Inc.
16.3.14. Newron Pharmaceuticals SpA
16.3.15. Novartis AG
16.3.16. Orion Corporation
16.3.17. UCB S.A.
16.3.18. Supernus Pharmaceuticals
16.3.19. Desitin Arzneimittel GmbH
16.3.20. Adamas Pharmaceutical Inc.
16.3.21. Amneal Pharmaceuticals
16.3.22. Sumitoma Dainippon pharma co ltd
16.3.23. Acorda Therapeutics Inc
16.3.24. Acadia Pharmaceuticals
16.3.25. Kyowa Kirin Inc

17. Primary Key Insights
  • INQUIRE BEFORE BUYING